GIT1 and gastric cancer: Previous studies have reported that GIT1 activates the MEK1/2–ERK1/2 signaling pathway.23 Therefore, we adopted MEK1/2 inhibitor to examine the role of MEK1/2–ERK1/2 signaling pathway in GC progression.